Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.

Novartis Pharmaceuticals924 enrolled

Overview

The study is a cohort observational, retrospective, non-interventional study.

Study period: Index date: The index date were defined as the first date of the first prescription of Sacubitril/Valsartan during inclusion period and this were used to establish the beginning of the follow-up period. Characterization period: 6 months period before the index date were used to characterize patients. Follow-up period: Any patients has at least 1 year of follow-up. Follow-up period went from index date to June 2020.

Study Type

OBSERVATIONAL

Enrollment

924

Conditions

Heart Failure

Interventions

Sacubitril/ValsartanDRUG

HF patients treated with Sac/Val

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: Consecutive ambulatory patients with a diagnosis of HF that attended the Outpatient Clinics for HF management and who have been prescribed Sacubitril/Valsartan from 01 October 2016 to 30 June 2019 (inclusion period) were included in the study. To allow for at least 1-year follow-up period for any patients, the observation period ended by 30 June 2020. In detail, all patients attending by outpatient clinics for the diagnosis and treatment of HF in the Italian Centers involved, with: * age ≥18 years old AND * at least one prescription of Sacubitril/Valsartan from 01 October 2016 to 30 June 2019 were included in the study. Exclusion Criteria: * Missing age or sex information.

Locations (1)

Novartis Investigative Site

Trieste, Italy

Outcomes

Primary Outcomes

Age

To describe the demographics

Time frame: Baseline

Gender

To describe the demographics

Time frame: Baseline

Number of patients with Ischemic heart disease

To evaluate clinical characteristics at baseline.

Time frame: Baseline

Number of patients with PCI/CABG: Percutaneous coronary intervention/coronary artery bypass grafting

To evaluate clinical characteristics at baseline.

Time frame: Baseline

Number of patients with moderate or severe mitral or aortic valvulopathy

To evaluate clinical characteristics at baseline.

Time frame: Baseline

Number of patients with Implanted prosthetic valve

To evaluate clinical characteristics at baseline.

Time frame: Baseline

Number of patients with ICD/CRT, Implantable Cardioverter Defibrillator/ Cardiac Resynchronization Therapy

To evaluate clinical characteristics at baseline.

Time frame: Baseline

Number of patients with Atrial fibrillation

To evaluate clinical characteristics at baseline.

Time frame: Baseline

Number of patients with prior hospitalization for HF

To evaluate clinical characteristics at baseline.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.